Withdrawal in newborns after exposure to psychotropic medications during pregnancy;Ontwenning bij de pasgeborene na blootstelling aan psychofarmaca tijdens de zwangerschap

Nederlands Tijdschrift voor Geneeskunde

Volumn 156, Issue 16, 2012, Pages

  Kieviet, Noera ^a   Dolman, Koert ^a   Wennink, Hanneke ^a   Heres, Marion ^a   Honig, Adriaan ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; HUMAN; NEWBORN; PREGNANCY; PRENATAL DRUG EXPOSURE; WITHDRAWAL SYNDROME;

EID: 84873555047     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Andersson L, Sundstromporomaa L, Bixo M, Wuff M, Bondestam K, Astrom M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: A population-based study. Am J Obstet Gynecol. 2003;189:148-54. (Pubitemid 36886540)
2. Bakker MK, Kölling P, van den Berg PB, de Walle HEK, de Jong-van den Berg LTW. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65:600-6. (Pubitemid 351365128)
3. Sie SD, Wennink JMB, van Driel JJ, Winkel te AGW, Boer K, Casteelen G, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed. 2011 (epub).
4. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-6. (Pubitemid 43213863)
5. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65:230-7.
6. Ter Horst PG, van der Linde S, Smit JP, den Boon J, van Lingen RA, Jansman FG, De Jong-van den Berg LT, Wilffert B. Clomipramine concentration and withdrawal symptoms in 10 neonates. Br J Clin Pharmacol. 2012;73:295-302 .
7. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 2005;162(11):2162-70. (Pubitemid 41598272)
8. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153:592-606. (Pubitemid 26133611)
9. Gentile S. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr. 2010;15:167-85.
10. Ferreira E, Carceller AM, Agogue C, et al. Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates. Pediatrics. 2007;119:52-9. (Pubitemid 46397842)
11. Uzun S, Kozumplik O, Jakovljević M, Sedić B. Side effects of treatment with benzodiazepines. Psychiatr Danub. 2010;22:90-3.
12. Nederlands Bijwerkingen Centrum Lareb. Geneesmiddelen, Zwangerschap en Borstvoeding. 5e dr. Den Bosch: Lareb; 2011.
13. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164:1214-20. (Pubitemid 47292410)
14. Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry. 2010;44:99-108.
15. Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci. 2008;45:107-13.
16. Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother- Infant Antidepressant Concentrations, Maternal Depression, and Perinatal Events. J Clin Psychiatry. 2011;72:994-1001.
17. Ververs T. Antidepressiva tijdens de zwangerschap: risico's voor moeder en kind [proefschrift]. Utrecht: Universiteit van Utrecht; 2009.
18. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis. J Perinatol. 2005;25:595-604. (Pubitemid 43118131)
19. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand. 2010;121:471-9.
20. Lundy B. Prenatal depression effects on neonates. Infant Behav Dev. 1999;22:119-29.
21. Misri S, Oberlander TF, Fairbrother N, et al. Relation between prenatal maternal mood and anxiety and neonatal health. Can J Psychiatry. 2004;49:68489.
22. Scheffers TPH, Enk JG. Gevolgen ssri-gebruik zwangeren bij de pasgeborene in de eerste 48 uur post partum. Tijdschr Kindergeneeskd. 2007;75:159-64.
23. Finnegan LP, Connaughton JF, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2:141-58.
24. Van Driel JJ, Wennink JHMB, Heres MHB, Honig A. Intra-uteriene blootstelling aan SSRI's: geen reden voor routinematige controle op hypoglykemie. Ned Tijdschr Geneeskd. 2010;154:A339.
25. Koren G. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? CMAJ. 2005;172:1457-9. (Pubitemid 40799750)
26. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010;44:978-96.
27. Vento M, de Vries LS, Alberola A, et al. Approach to seizures in the neonatal period: A European Perspective. Acta Paediatr. 2010;99:497-501.
28. Klinger G, Frankenthal D, Merlob P, et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol. 2011;31:615-20.